Cerus Corporation

Cerus Corporation is an American biotechnology company headquartered in Concord, California, dedicated to safeguarding the global blood supply. The company's core mission is to establish its proprietary INTERCEPT Blood System as the standard of care for transfused blood components worldwide, providing vital technologies and pathogen-protected blood products to blood centers, hospitals, and patients.

Cerus's key offerings center around the INTERCEPT Blood System, which includes systems for platelets and plasma, both globally available with CE mark and FDA approval. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex, used to treat bleeding associated with fibrinogen deficiency. The company is also advancing its INTERCEPT red blood cell system, which is currently under regulatory review in Europe and in late-stage clinical development in the U.S. Cerus serves market segments including blood centers, hospitals, and national blood services across the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international regions.

In recent leadership changes, Vivek Jayaraman assumed the role of President and Chief Executive Officer effective July 1, 2026, with former CEO William 'Obi' Greenman transitioning to Executive Chairman. The company recently closed a new debt facility of up to $110 million in June 2026 and reported strong first-quarter 2026 financial results, raising its full-year product revenue guidance. Cerus continues to highlight its innovations and global experience with the INTERCEPT Blood System at major industry events, such as the 39th International ISBT Congress in June 2026. INTERCEPT-treated platelets are currently considered the standard of care in the United States, accounting for approximately two-thirds of all transfused platelets.